Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn Pharmaceuticals. The...
The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine. The move was part of several announced by the...
The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria. “This marks another significant milestone for Revive and...
Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year. Analyst Ben Haynor writes that top-line data for Dipexium’s two Phase 3...
Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...
Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective...
Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may...
Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An...
Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative...
OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...
Oramed Pharmaceuticals (NASDAQ:ORMP) has received a $6.5-million milestone payment from Hefei Tianhui Incubator of Technologies (HTIT) under a December 2015 license and investment agreement. The payment follows Oramed’s...
The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26. ProbuphineProbuphine was developed using Titan’s long...
Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain. In a new trial with the...
Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s Microbe conference...
NBC News has become the latest media outlet to feature Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for people addicted to heroin and prescription painkillers. As an implantable version of oral buprenorphine...
The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and...
Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence, at...
Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug Dependence 78th...
QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics. Under the accord, each outstanding...
Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month...
ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or...